Hospital
Orlando Health Central, INC.
Orlando Health Central, INC. was paid $12.50M by Medicaid between Jan 2018 and Dec 2024, across 198 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoORLANDO HEALTH CENTRAL, INC.
OCOEE, FL 34761
OCOEE, FL 34761
33aNPI1033475959assigned 04/04/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.50M
24GClaims579,175
24DCodes billed198
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#41 of 163
Median peer was paid$4.77M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,894 | $415K | |
| 2019 | 120,774 | $1.45M | |
| 2020 | 88,547 | $1.02M | |
| 2021 | 103,279 | $2.17M | |
| 2022 | 105,243 | $2.99M | |
| 2023 | 79,852 | $2.99M | |
| 2024incomplete | 44,586 | $1.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 39,508 | 36,510 | $3.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 34,929 | 30,658 | $2.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 14,031 | 12,452 | $1.22M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.6% | 5,062 | 4,572 | $821K |
| 80053 | Comprehensive metabolic panel | 5.2% | 36,932 | 31,141 | $647K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 10,955 | 9,060 | $533K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,460 | 1,319 | $261K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.0% | 2,008 | 1,815 | $253K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,869 | 2,714 | $245K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 6,273 | 5,514 | $207K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 4,455 | 1,007 | $136K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,535 | 1,402 | $121K |
186 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,120 | $91K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,301 | $72K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,731 | $68K |
| 87631 | <1% | 2,766 | $59K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 925 | $53K |
| G0378 | Hospital observation service, per hour | <1% | 8,915 | $50K |
| 87088 | <1% | 4,995 | $49K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,729 | $43K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 915 | $40K |
| 87430 | <1% | 1,745 | $39K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,396 | $39K |
| 84703 | <1% | 9,261 | $39K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,218 | $35K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,608 | $34K |
| 81003 | <1% | 15,972 | $33K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,460 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,497 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,607 | $31K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,535 | $31K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,198 | $28K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 10,779 | $26K |
| 84702 | <1% | 3,474 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,598 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,203 | $24K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,546 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,829 | $23K |
| 73562 | <1% | 1,514 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,725 | $19K |
| 82948 | <1% | 3,594 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,018 | $18K |
| 73610 | <1% | 1,126 | $17K | |
| 87210 | <1% | 3,967 | $17K | |
| 73130 | <1% | 1,076 | $17K | |
| 73630 | <1% | 1,350 | $16K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,448 | $16K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 179 | $15K |
| 87081 | <1% | 2,202 | $14K | |
| 97597 | <1% | 188 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 848 | $14K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,256 | $14K |
| 76801 | <1% | 1,952 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,794 | $13K |
| 73030 | <1% | 1,119 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,649 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,342 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,031 | $11K |
| 81025 | <1% | 9,277 | $11K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,660 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,878 | $11K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,006 | $11K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 939 | $10K |
| 96376 | <1% | 2,828 | $10K | |
| 72131 | <1% | 1,603 | $10K | |
| 87420 | <1% | 385 | $10K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 297 | $9K |
| 73110 | <1% | 564 | $9K | |
| 97161 | <1% | 337 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 414 | $8K |
| 93971 | <1% | 850 | $8K | |
| 93017 | <1% | 376 | $8K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 352 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 876 | $8K |
| 83735 | <1% | 10,521 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,342 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,622 | $7K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 388 | $7K |
| 87077 | <1% | 1,071 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,685 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 326 | $7K |
| 70486 | <1% | 454 | $7K | |
| 86900 | <1% | 1,928 | $6K | |
| 84484 | <1% | 15,487 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,660 | $6K |
| 90715 | <1% | 361 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 998 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 312 | $6K |
| 85027 | <1% | 6,587 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,755 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,135 | $5K |
| J3490 | Unclassified drugs | <1% | 692 | $5K |
| 74018 | <1% | 534 | $5K | |
| 82962 | <1% | 2,074 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 470 | $5K |
| 81001 | <1% | 11,671 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 463 | $5K |
| 70491 | <1% | 15 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 390 | $5K |
| 92587 | <1% | 63 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,067 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 354 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,185 | $3K |
| 85730 | <1% | 3,444 | $3K | |
| 85610 | <1% | 3,644 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $3K |
| 83690 | <1% | 10,222 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $2K |
| 83880 | <1% | 2,944 | $2K | |
| 82550 | <1% | 3,873 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 237 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 738 | $2K |
| 73090 | <1% | 193 | $2K | |
| 87207 | <1% | 123 | $2K | |
| 85379 | <1% | 2,862 | $2K | |
| 73590 | <1% | 332 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,468 | $2K |
| 10061 | <1% | 85 | $2K | |
| 80061 | Lipid panel | <1% | 2,725 | $1K |
| 73140 | <1% | 25 | $1K | |
| 73080 | <1% | 110 | $1K | |
| 87158 | <1% | 725 | $1K | |
| 84439 | <1% | 1,114 | $1K | |
| 86901 | <1% | 1,904 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 39 | $914.72 |
| 73552 | <1% | 101 | $888.14 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 18 | $758.44 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 325 | $747.92 |
| 87186 | <1% | 1,819 | $662.40 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,065 | $650.71 |
| 72128 | <1% | 433 | $647.79 | |
| 80320 | <1% | 776 | $639.73 | |
| 29125 | <1% | 40 | $592.19 | |
| 12001 | <1% | 29 | $555.53 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 62 | $520.29 |
| 85018 | <1% | 12 | $491.36 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 347 | $453.43 |
| 12011 | <1% | 58 | $410.05 | |
| 86850 | <1% | 474 | $355.91 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 240 | $340.74 |
| 93970 | <1% | 30 | $318.82 | |
| 87641 | <1% | 25 | $266.86 | |
| 82274 | <1% | 57 | $260.52 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,658 | $237.77 |
| 99218 | <1% | 173 | $231.68 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $227.88 |
| 72170 | <1% | 13 | $209.64 | |
| 86308 | <1% | 56 | $198.64 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 537 | $167.62 |
| 80329 | <1% | 236 | $161.83 | |
| 87040 | <1% | 232 | $136.69 | |
| 71250 | <1% | 16 | $113.24 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 32 | $102.54 |
| 72100 | <1% | 25 | $97.45 | |
| 81015 | <1% | 107 | $92.57 | |
| 85652 | <1% | 237 | $92.07 | |
| 82607 | <1% | 191 | $68.03 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 494 | $62.71 |
| 82728 | <1% | 116 | $62.38 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 51 | $55.96 |
| 83605 | <1% | 728 | $34.49 | |
| 83550 | <1% | 89 | $28.18 | |
| 83540 | <1% | 107 | $23.17 | |
| 85045 | <1% | 16 | $18.69 | |
| 86140 | <1% | 67 | $16.97 | |
| 82746 | <1% | 53 | $7.84 | |
| 87220 | <1% | 2,095 | $7.43 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 235 | $3.35 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 286 | $2.18 |
| 87660 | 0% | 39 | $0.00 | |
| 87481 | 0% | 239 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 45 | $0.00 |
| 85007 | 0% | 226 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 82570 | 0% | 13 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 17 | $0.00 |
| 82272 | 0% | 14 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 15 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 16 | $0.00 |
| 87480 | 0% | 39 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 102 | $0.00 |
| 73060 | 0% | 13 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 17 | $0.00 |
| 73502 | 0% | 14 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 238 | $0.00 |
| 87486 | 0% | 14 | $0.00 | |
| 84132 | 0% | 52 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 204 | $0.00 |
| 87510 | 0% | 39 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 40 | $0.00 |
| 87581 | 0% | 14 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 24 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 17 | $0.00 |
| 87070 | 0% | 15 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 13 | $0.00 |
| 0352U | 0% | 41 | $0.00 | |
| 82553 | 0% | 36 | $0.00 | |
| 85651 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUELLER, MICHAEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Wichita Anesthesiology Chartered | Wichita, KS | $391K |
| Orlando Health Central, INC. | Winter Garden, FL | $210K |
| Michael J Mueller MD PC | Flint, MI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.